Emmaus Q2 Revenue Jumps 124% on NeoImmuneTech License Deal
EMMA sits 62% above its 52-week low of $0.007.
Summary
Emmaus reported Q2 2026 net income of $1.3 million, swinging from a $1.1 million loss a year ago, driven by a 124% jump in net revenues to $6.3 million. The surge came from recognizing upfront payment and royalties under the NeoImmuneTech license agreement effective May 15, 2026, which also transferred the sales force and cut operating expenses to $2.1 million from $3.0 million. Cash stands at $2.8 million, up from $2.1 million at year-end. This follows the 10-Q filed earlier today that flagged a going concern warning and a $60.1 million working capital deficit, so the improved operating results are a bright spot but liquidity remains tight. The NIT deal's royalty stream will be key to watch in coming quarters.
At the time of this announcement, EMMA was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $807.2K. The 52-week trading range was $0.01 to $0.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.